PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - NYSE:MD - US58502B1061 - Common Stock
16.97 USD
-0.42 (-2.42%)
16.97 USD
0 (0%)
Overall MD gets a fundamental rating of 5 out of 10. We evaluated MD against 101 industry peers in the Health Care Providers & Services industry. MD has only an average score on both its financial health and profitability. MD scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, MD could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
MD had a positive operating cash flow in the past year.
In multiple years MD reported negative net income over the last 5 years.
In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
MD's Return On Assets of 5.23% is fine compared to the rest of the industry. MD outperforms 79.21% of its industry peers.
With a decent Return On Equity value of 13.18%, MD is doing good in the industry, outperforming 79.21% of the companies in the same industry.
MD has a Return On Invested Capital of 9.55%. This is amongst the best in the industry. MD outperforms 80.20% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MD is in line with the industry average of 9.33%.
The last Return On Invested Capital (9.55%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROIC | 9.55% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
Looking at the Profit Margin, with a value of 5.66%, MD is in the better half of the industry, outperforming 79.21% of the companies in the same industry.
MD has a Operating Margin of 10.97%. This is in the better half of the industry: MD outperforms 79.21% of its industry peers.
In the last couple of years the Operating Margin of MD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
MD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MD has more shares outstanding
The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
MD has an Altman-Z score of 1.99. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
MD has a Altman-Z score (1.99) which is in line with its industry peers.
MD has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as MD would need 2.68 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.68, MD belongs to the top of the industry, outperforming 80.20% of the companies in the same industry.
A Debt/Equity ratio of 0.70 indicates that MD is somewhat dependend on debt financing.
MD has a Debt to Equity ratio of 0.70. This is comparable to the rest of the industry: MD outperforms 52.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 1.99 |
ROIC/WACC1.04
WACC9.2%
2.3 Liquidity
A Current Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
MD has a better Current ratio (1.80) than 69.31% of its industry peers.
MD has a Quick Ratio of 1.80. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio of 1.80. This is in the better half of the industry: MD outperforms 70.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.39%, which is quite impressive.
Measured over the past years, MD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -15.01% on average per year.
The Revenue has decreased by -3.08% in the past year.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 3.76% on average per year.
MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.34% yearly.
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y3.76%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.38 indicates a reasonable valuation of MD.
Based on the Price/Earnings ratio, MD is valued cheaper than 91.09% of the companies in the same industry.
When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (26.10), we can say MD is valued rather cheaply.
With a Price/Forward Earnings ratio of 9.00, the valuation of MD can be described as very reasonable.
Based on the Price/Forward Earnings ratio, MD is valued cheaply inside the industry as 91.09% of the companies are valued more expensively.
MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.52, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.38 | ||
| Fwd PE | 9 |
4.2 Price Multiples
86.14% of the companies in the same industry are more expensive than MD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 94.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.51 | ||
| EV/EBITDA | 6.82 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y12.52%
EPS Next 3Y9.51%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.97
-0.42 (-2.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.31%
Inst Owner Change0.18%
Ins Owners1.9%
Ins Owner Change8.02%
Market Cap1.48B
Revenue(TTM)1.94B
Net Income(TTM)109.92M
Analysts78.67
Price Target17.09 (0.71%)
Short Float %3.22%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.94%
Min EPS beat(2)21.14%
Max EPS beat(2)32.73%
EPS beat(4)4
Avg EPS beat(4)26.19%
Min EPS beat(4)15.9%
Max EPS beat(4)34.96%
EPS beat(8)6
Avg EPS beat(8)10.2%
EPS beat(12)6
Avg EPS beat(12)3.22%
EPS beat(16)9
Avg EPS beat(16)4.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.44%
Revenue beat(4)1
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-2.84%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)1.01%
PT rev (3m)-2.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.33%
EPS NY rev (1m)0%
EPS NY rev (3m)7.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.38 | ||
| Fwd PE | 9 | ||
| P/S | 0.76 | ||
| P/FCF | 6.51 | ||
| P/OCF | 6.04 | ||
| P/B | 1.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.82 |
EPS(TTM)1.81
EY10.67%
EPS(NY)1.89
Fwd EY11.12%
FCF(TTM)2.61
FCFY15.36%
OCF(TTM)2.81
OCFY16.55%
SpS22.29
BVpS9.57
TBVpS-4.8
PEG (NY)0.39
PEG (5Y)N/A
Graham Number19.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROCE | 12.09% | ||
| ROIC | 9.55% | ||
| ROICexc | 11.91% | ||
| ROICexgc | 104.6% | ||
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A | ||
| FCFM | 11.7% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 73.88% | ||
| Cap/Sales | 0.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.31% | ||
| Profit Quality | 206.51% | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.99 |
F-Score7
WACC9.2%
ROIC/WACC1.04
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y3.76%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
EBIT growth 1Y39.69%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year49.88%
EBIT Next 3Y15.85%
EBIT Next 5YN/A
FCF growth 1Y63.28%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y43.72%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 5 / 10.
How financially healthy is PEDIATRIX MEDICAL GROUP INC?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 5 / 10.
What is the expected EPS growth for PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Earnings per Share (EPS) of PEDIATRIX MEDICAL GROUP INC (MD) is expected to grow by 23.94% in the next year.